-transparent.png){kind=logo}
To study the immunogenicity and reactogenicity of an inactivated hepatitis A vaccine, 204 healthy individuals were randomized into three equal groups, each to receive a different vaccine lot. Each subject received a total of three doses, each of 720 ELISA units of hepatitis A vaccine HM175, according to a 0 and 1 month primary vaccination schedule, with a booster dose given at month 6. Side effects were low and were < 30% after the second injection. All subjects but one had antibodies to hepatitis A virus two months after the first dose of vaccine. At month 6 all vaccinees had seroconverted. There were no differences between the three vaccine lots with respect to side effects, seroconversion rates and geometric mean titre of antibodies. We conclude that the three lots of inactivated hepatitis A vaccine are safe, well tolerated and equally immunogenic.
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
January 1987,
Postgraduate medical journal,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
July 2004,
Clinical therapeutics,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
January 1998,
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
December 1994,
Journal of medical virology,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
January 1999,
The National medical journal of India,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
November 1988,
Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
January 1999,
Vaccine,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
January 1994,
Israel journal of medical sciences,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
June 2008,
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
L Theilmann, and
B Kallinowski, and
K Gmelin, and
F Hofmann, and
N Scheiermann, and
B Wohland, and
H Stickl, and
H Maiwald, and
F K Moriabadi, and
H L Bock
March 1996,
European journal of pediatrics,
